Objective: GlycA, a novel NMR biomarker of inflammation, has been associated with incident cardiovascular disease (CVD) in the general population, but its association with CVD among HIV-infected individuals is unknown. We examined the associations between GlycA and subclinical coronary plaque among HIV-infected and HIV-uninfected men participating in Multicenter AIDS Cohort Study (MACS).
Introduction
With the use of combination antiretroviral therapy (ART), individuals infected with HIV are now living longer and have higher rates of cardiovascular disease (CVD) events [1, 2] and an increased prevalence of subclinical coronary atherosclerosis compared with HIVuninfected individuals of similar age and risk factors [3, 4] . Atherosclerosis is an inflammatory process [5, 6] and chronically elevated systemic inflammation conferred by HIV infection may explain this increased CVD risk [7] [8] [9] . Traditional CVD risk stratification tools often inadequately depict CVD risk in HIV infection [10] . In the general population, biomarkers of inflammation, especially high-sensitivity C-reactive protein (hsCRP), have been shown to independently predict incident CVD events [11, 12] . However, hsCRP may predict risk less well among HIV-infected individuals compared with other inflammatory markers [13] .
There is a further need to identify biomarkers that can more accurately capture the inflammatory risk among individuals with HIV infection. The Multicenter AIDS Cohort Study (MACS) previously reported associations of biomarkers of monocyte activation, systemic inflammation and coagulation with subclinical coronary artery disease (CAD) in men with and without HIV infection [8, 9] . GlycA is a novel composite biomarker of systemic inflammation measured by nuclear magnetic resonance (NMR) spectroscopy and may be less prone to day-to-day fluctuations [14] . It reflects mainly the serum concentrations and glycosylation states of five abundant acute-phase reactants: a1-acid glycoprotein, haptoglobin, a1-antitrypsin, a1-antichymotrypsin and transferring [14] . In the general population, higher levels of GlycA have been independently associated with incident CVD events [15] [16] [17] [18] [19] , diabetes mellitus [20] , and cardiovascular and allcause mortality [15, 21, 22] . GlycA levels were associated with subclinical coronary atherosclerosis independent of traditional CVD risk factors and hsCRP in patients with psoriasis [23] but not among patients with lupus [24] . Whether GlycA is associated with increased subclinical coronary atherosclerosis among HIV-infected individuals is unknown.
The aims of the present study were two-fold: first, we investigated whether GlycA levels are associated with the presence and burden of subclinical coronary atherosclerosis as ascertained by cardiac computed tomography (CT) imaging. Second, we determined whether such associations differed by HIV serostatus. We hypothesized that: GlycA levels will be higher among HIV-infected participants, GlycA will be associated with subclinical coronary atherosclerosis measures beyond traditional CVD risk factors and traditional inflammatory markers, and the magnitude of the association of GlycA with subclinical coronary atherosclerosis will be more pronounced among HIV-infected individuals compared with HIV-uninfected individuals.
Methods Population
Detailed description of the MACS has been previously published [25] . Briefly, MACS is an ongoing multicenter prospective cohort study of the natural and treated histories of HIV-1 infection among MSM. MACS enrolled a total of 7352 HIV-infected and HIV-uninfected participants during three periods (1984-1985, 1987-1991, and 2001-2003 ) from four US sites: Baltimore, Maryland/ Washington, DC; Chicago, Illinois; Pittsburgh, Pennsylvania and Los Angeles, California [25] .
Between the years of 2010 and 2013, 1006 MACS participants aged 40-70 years, weighing less than 136 kg, without a history of cardiac surgery or percutaneous coronary intervention, participated in a MACS Cardiovascular Ancillary Study [3] . These participants underwent noncontrast cardiac CT scanning to measure coronary artery calcium (CAC) scores. Among men who completed a noncontrast cardiac CT, 759 also met the inclusion criteria to undergo contrast coronary CT angiography (CTA) to measure total plaque burden, plaque composition and coronary stenosis. Exclusion criteria for CTA were contrast allergy, atrial fibrillation, or chronic kidney disease [estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m 2 within 30 days of imaging).
Of the 1006 MACS-CVD2 participants enrolled, we excluded participants with missing GlycA levels (n ¼ 70) and CAC measurement (n ¼ 1), resulting in 935 eligible participants for assessment of GlycA with CAC, 715 of whom also underwent CTA (Fig. 1) . The Institutional Review Boards of all participating centers approved the studies and all participants provided written informed consent.
Measurement of GlycA
Blood was drawn on the day of cardiac imaging after a 12-h fast. All samples were stored at À 80 8C until they were subsequently thawed for NMR analysis. GlycA levels (mmol/l) in ethylenediaminetetraacetic acid (EDTA) plasma samples were quantified from NMR LipoProfile test spectra collected at LipoScience (now LabCorp, Raleigh, North Carolina, USA) as previously described [14] . The intra-assay and inter-assay coefficients of variability for GlycA measurement were 1.9 and 2.6%, respectively [15] . Previous work by Otvos et al. [14] found that GlycA levels were similar when measured in serum vs. plasma samples, fasting vs. nonfasting states, and after shortterm vs. long-term storage.
Cardiac computed tomography and assessment of subclinical coronary atherosclerosis Primary outcomes of interest included: presence of CAC (Agatston score >0), presence of any coronary plaque on CTA (total plaque score >0), and moderate-to-severe coronary artery stenosis (!50%). Secondary outcomes included measures of plaque composition: noncalcified plaque score greater than zero, mixed plaque score greater than zero, and calcified plaque score greater than zero.
Cardiac CT scans were obtained following procedures as previously described [26] . Briefly, participants received a beta-blocker or calcium channel blocker if needed for heart rate control just before the time of scanning, followed by sublingual nitroglycerin before administration of intravenous contrast unless contraindicated. Coronary CTA was performed with electrocardiogram-triggered protocols and median radiation dose of 1.9 mSv (interquartile range, 1.7-2.7 mSv). CT images were analyzed at the core CT reading center (Los Angeles Biomedical Research Institute at Harbor-UCLA) by trained, experienced readers blinded to participant clinical information.
CAC scores obtained from noncontrast CTs were calculated using the Agatston method [27] . Coronary CTA images were examined to characterize coronary plaque burden (presence, size, and composition of plaque) and degree of coronary stenosis in all segments following the modified 15-segment model of the American Heart Association [28] .
Total plaque score was calculated as the sum of individual plaque size scores across all coronary segments that showed any plaque, with a maximum score of 45 [29] . Noncalcified plaque was defined as any discernable structure clearly assignable to the vessel wall with a CT density less than the contrast-enhanced coronary lumen but greater than the surrounding connective tissue in at least two independent planes. Calcified plaque was defined as any structure with CT attenuation greater than 130 Hounsfield Units visualized as being distinct from the intravascular lumen in at least two independent planes. The total noncalcified plaque, mixed plaque, and calcified plaque scores were calculated as the sum of the respective scores across all coronary segments.
Covariates
As part of routine MACS visits, study participants are seen every 6 months and data are collected regarding CVD risk factors and HIV clinical variables by questionnaires, physical examination, and laboratory tests using standard protocols [3, 25] . For this analysis, we used clinical data collected at the MACS visit closest to the CT date. The laboratory measures were obtained from blood samples drawn at same visit as the CT scan.
Covariates included in our models were age, race/ ethnicity, scanning center, HIV serostatus, study cohort (pre/post2001 to account for recruitment cohort effect), measured SBP, measured BMI, fasting blood glucose, total cholesterol, high-density lipoprotein (HDL) cholesterol, pack-years of smoking, use of antihypertensive, lipid-lowering or antidiabetic medications, eGFR, hepatitis C virus (HCV) infection status, and serum levels of traditional inflammatory biomarkers (hsCRP, IL-6, D-dimer and fibrinogen). We also chose to evaluate þ (sCD163), and chemokine (C-C motif) ligand two (CCL2) because they have previously been shown to be elevated in HAARTtreated HIV-infected men and to be associated with atherosclerosis [9] . Among the HIV-infected men, the HIV disease characteristics evaluated included plasma HIV viral load (determined by the Roche ultrasensitive assay with a lower limit detection of 50 copies/ml) [30] , CD4
þ T-lymphocyte cell counts/ml (CD4 þ ) measured by flow cytometry, history of AIDS-defining illness, and use and duration of HAART. The detailed measurement protocols and definitions for all of these covariates have been previously published [3, 8, 31] .
Statistical analysis
Baseline characteristics were stratified by quartiles of GlycA levels for the whole cohort and by HIV serostatus. Continuous variables were presented as the mean (SD) and categorical variables as frequencies (percentage). Skewed variables were presented as medians (25th-75th percentiles).
We used multivariable Poisson regression models with robust variance estimation to assess the association between GlycA levels, presented per SD increment, with prevalent subclinical coronary atherosclerosis (CAC, coronary stenosis !50%, any plaque, calcified plaque, noncalcified plaque, and mixed plaque). Among men with plaque present, a multivariable linear regression model was used to assess for associations of GlycA with plaque burden (extent). As plaque scores were not normally distributed, they were natural-log transformed.
Models were progressively adjusted as follows: Model 1 was adjusted for age, race/ethnicity, scanning center, HIV serostatus, and study cohort (pre/post2001). Model 2, our primary analytical model, was further adjusted for established CVD risk factors including SBP, BMI, physical activity level, use of hypertension medications, diabetes medications, and lipid-lowering medications, fasting glucose, total and HDL cholesterol, pack-years of tobacco smoking, eGFR and HCV infection status. We then performed two exploratory models to determine whether GlycA levels might be associated with subclinical coronary atherosclerosis independent of other established inflammatory marker levels. Model 3 was additionally adjusted for levels of hsCRP, D-dimer, IL-6, and fibrinogen (i.e. traditional markers of systemic inflammation). Model 4 was additionally adjusted for sCD163, sCD14, and CCL2 levels (i.e. markers of monocyte activation).
All results were presented for the overall cohort, and then stratified by HIV serostatus. In the stratified analyses for HIV-infected individuals only, a supplemental Model 5 was additionally adjusted for HIV-related factors (CD4 Effect modification (i.e. interaction testing) by HIV serostatus was evaluated with the Wald test. Statistical significance was established at a two-tailed P value less than 0.05.
Results
Characteristics of the study population The characteristics of the MACS participants included in the present study, overall and by quartiles of GlycA, are summarized in Table 1 . The mean (SD) age of participants was 54 (7) years. The sample included a large proportion of blacks (31.2%) and HIV-infected individuals (63.0%). Higher quartiles of plasma GlycA were significantly positively associated with HCV infection, HIV infection, levels of hsCRP, IL-6, fibrinogen, sCD163, sCD14, CCL2, and CAC (Table  1) . GlycA levels were higher in HIV-infected compared with HIV-uninfected men (397 AE 68 vs. 380 AE 60 mmol/ l, P ¼ 0.0001) and higher for men with detectable viral load vs. undetectable (413 AE 79 vs. 393 AE 65 mmol/l, P ¼ 0.004; Supplemental Figure 1 , http://links.lww.-com/QAD/B400). The characteristics of the study population by HIV serostatus is shown in Supplemental Table 1 , http://links.lww.com/QAD/B400.
Correlation of GlycA with demographic, clinical, inflammatory markers, and HIV-related factors For lifestyle and clinical parameters, plasma GlycA levels positively correlated with smoking pack-years and HCV infection status and inversely correlated with HDL cholesterol levels and physical activity level among HIVinfected participants (Table 2) . Among HIV-uninfected participants, significant correlations included positive correlations with BMI, fasting blood glucose, and smoking pack-years, and inverse correlation with HDL cholesterol ( Table 2 ). The use of protease inhibitors was positively correlated, and nadir CD4 þ cell count was inversely correlated with GlycA levels among HIVrelated factors examined. Among inflammatory markers, GlycA was significantly correlated with hsCRP, D-dimer, IL-6, fibrinogen, and sCD14 levels among both HIVinfected and HIV-uninfected participants (Table 2) .
GlycA and the prevalence of subclinical coronary atherosclerosis Table 3 and Supplemental Figure 2 , http://links.lww.-com/QAD/B400 summarize the associations of GlycA levels with the prevalence of subclinical coronary atherosclerosis by noncontrast cardiac CT and CTA. In demographic-adjusted models (model 1), one SD increment in plasma GlycA was significantly associated with greater prevalence of CAC (Agatston score >0), coronary artery stenosis at least 50%, mixed plaque and calcified plaque with prevalence ratios [95% confidence interval (CI) of 1.12 (1.07-1.18), 1.33 (1.13-1.56), 1.12 (1.01-1.24) and 1.14 (1.04-1.26)], respectively (Table  3) . For CAC, coronary stenosis, and calcified plaque, these associations remained significant even after further adjustments for traditional CVD risk factors in our main model (Model 2) and after adjustment for traditional inflammatory marker levels (Model 3). However, the association for coronary stenosis was attenuated after adjusted for monocyte activation markers (Model 4). We did not find an association with noncalcified plaque in any model. In sensitivity analyses when we compared the top quartile of GlycA with the bottom quartile, findings were similar to the main analyses using GlycA as a continuous measure (Supplemental Table 2 , http://links.lww.com/ QAD/B400).
GlycA and plaque burden
Among participants with plaque present on cardiac CT and CTA (respective scores >0), each SD increment in plasma GlycA was significantly associated with greater burden of log-transformed CAC, total plaque, and mixed plaque scores (Table 4 , model 1). Again, these associations Table 1 . Characteristics of participants undergoing cardiac computed tomography by GlycA quartiles, the MACS-CVD2 study (2010) (2011) (2012) (2013) remained significant even after further adjustments for traditional CVD risk factors in our primary model (model 2) and after additional adjustment for hsCRP, D-dimer, IL-6, and fibrinogen levels (model 3). The associations with total plaque and mixed plaque remained significant after adjustment for monocyte activation markers (model 4). In sensitivity analyses, when we compared the top quartile of GlycA levels with the bottom quartile, findings were similar to the main analyses using GlycA as a continuous measure (Supplemental Table 3 , http://links. lww.com/QAD/B400).
GlycA with subclinical coronary atherosclerosis by HIV serostatus Overall, the association of GlycA with subclinical atherosclerosis did not significantly differ by HIV serostatus, with P values for interaction being nonsignificant (Supplemental Figure 2 , http://links.lww.com/ QAD/B400). The results were generally similar, although associations of GlycA with total plaque and mixed plaque seemed weaker among HIV-infected men (Table 4) .
Discussion
In this well characterized cohort of HIV-infected and HIV-uninfected men, we demonstrated that: GlycA levels were higher in HIV-infected men (especially with higher viral loads) than uninfected men. GlycA levels were significantly and positively correlated with levels of hsCRP, D-dimer, IL-6, fibrinogen, and sCD14 among both HIV-infected and HIV-uninfected men GlycA was significantly associated with multiple CT measures of subclinical coronary atherosclerosis, and the results were generally similar among HIV-infected and HIV-uninfected men. Specifically, higher GlycA levels were significantly associated with the presence of CAC, coronary stenosis, and calcified plaque (but not with noncalcified plaque) even after controlling for levels of other markers of systemic inflammation including hsCRP, D-dimer, IL-6, and fibrinogen, as well as markers of monocyte activation including sCD163, sCD14, and CCL2. Also, higher GlycA levels were significantly associated with a higher burden of CAC, total plaque, and mixed plaque, independent of hsCRP, D-dimer, IL-6, and fibrinogen. Taken together, our findings suggest that GlycA is a promising marker of subclinical coronary atherosclerosis regardless of HIV serostatus.
Since the two-hit hypothesis of atherosclerosis was proposed by Ross [5] , consisting of an inflammatory response following an initial endothelial injury mediated by cholesterol, robust epidemiologic studies have underscored the potential role of inflammation in atherogenesis. Yet this inflammatory hypothesis remained largely unproven until recently. In the CANTOS randomized clinical trial, Ridker et al. [32] reported that the use of anti-inflammatory therapy, canakinumab to target the interleukin-1b innate immunity pathway significantly lowered the rate of recurrent CVD events compared with placebo, independent of lipid-level lowering. This opens the door for future preventive strategies targeting inflammation for CVD prevention.
Inflammatory biomarkers, especially hsCRP have been shown to predict future risk of incident CVD in the general population beyond traditional CVD risk factor assessment [11, 12] . Thus, inflammatory biomarkers have been shown to be useful for the early identification of high-risk individuals who may benefit from targeted preventive strategies, such as statin therapy in order to reduce CVD morbidity and mortality. However, these biomarker levels have been shown to be prone to fluctuations by many variables and have also been shown not to consistently predict both subclinical and clinical CVD events in populations with chronic inflammatory conditions such as HIV infection, psoriasis, and rheumatoid arthritis [23] . GlycA is a composite inflammatory biomarker that may bridge this gap. Indeed, GlycA has been shown to be a biomarker of chronic inflammation [33] and its utility as a CVD risk assessment tool has been explored in some chronic inflammatory conditions [23, 24, 34, 35] . For example, Joshi et al. [23] found an association of GlycA levels with subclinical coronary atherosclerosis among psoriatic patients beyond traditional CVD risk factors and hsCRP. GlycA may be a useful marker of disease severity among patients with rheumatoid arthritis [35] and is elevated in systemic lupus erythematosus [24] . However, unlike our findings noted in a cohort enriched with individuals living with HIV-infection, Chung et al. [24] did not find any significant association of GlycA with CAC among lupus patients, although their sample size was small. To our knowledge, the present study is the first to test the relationship of GlycA with subclinical coronary atherosclerosis among HIV-infected individuals and compared with similar HIV-uninfected individuals in the MACS cohort. GlycA was associated with multiple measures of subclinical atherosclerosis in this population, with generally similar results by HIV serostatus. Although hsCRP is a validated CVD risk stratification tool in the general population, it may not be as useful in predicting the risk of future CVD events among HIVinfected individuals [13] . In a prior analysis from the MACS study, significant associations of IL-6, ICAM-1, sTNFR I, and sTNFR II, but not hsCRP, were found with subclinical coronary atherosclerosis among HIVinfected men [8] . Higher levels of IL-6 and D-dimer may be stronger markers of CVD risk in HIV-infection than hsCRP [13, 36] , although we did additionally adjust for those markers in our supplemental models. In sum, these findings highlight the complex nature of the interactions between HIV infection, antiretroviral medication use, and systemic inflammation that may work in synergy to promote atherogenesis [37] . Although we recognize that these biomarkers reflect different domains in the inflammatory cascade, GlycA integrates multiple inflammatory pathways, and thus may better capture the degree of systemic inflammation [38] . Kelesidis et al. [37] found that GlycA was the only biomarker of inflammation among hsCRP, IL-6, and D-dimer that decreased in all groups after treatment with atazanavir-based, raltegravirbased, darunavir-based initial ART. Collectively, these findings support the notion that GlycA may be a reliable biomarker of subclinical CVD risk and treatment response in HIV.
This study benefited from detailed phenotyping of subclinical coronary atherosclerosis including plaque composition and burden using both noncontrast cardiac CT scans and CTA in a large, well characterized cohort. Nonetheless, the findings of our study should be considered in the context of several limitations. First, by study design, the MACS enrolled only MSM, so the present findings may not apply to women or to individuals who acquired HIV infection through other behaviors. Second, we utilized a cross-sectional study design and lack temporality to determine the direction of the observed associations between the contemporaneously measured GlycA and subclinical coronary atherosclerosis. Future studies are needed to determine whether GlycA levels are predictive of incident CVD events among HIV-infected individuals. Our study is observational, and residual confounding may in part explain the associations seen despite our rigorous adjustment for numerous traditional CVD risk factors and other common inflammatory markers of risk. We did not have measures of immunoglobulins (IgG) to consider in our analysis. Finally, false positive results associated with simultaneously testing multiple outcomes are possible. However, this is less likely given the level of significance and consistency of most of the associations highlighted in this article.
In conclusion, GlycA levels, integrating multiple inflammatory pathways, are higher among HIV-infected men than HIV-uninfected men and correlate well with other inflammatory and monocyte activation biomarker levels, as well as with multiple measures of CT subclinical coronary atherosclerosis. Our study suggests the potential use of GlycA in CVD risk stratification in HIV patients, similar to that in HIV-uninfected persons, but further study is needed in this area.
